Science-Driven. Mission-Focused. Clinically Ready.
Leveraging cutting-edge neuroscience to tackle unmet needs in ophthalmology and beyond.
EIR Biopharma is advancing next-generation therapeutics that address vision loss at the molecular source, through modulation of ephrin receptor signaling, a master regulator of neural development and disease.
Our lead programs target glaucoma, dry age-related macular degeneration (AMD), diabetic retinopathy, and Stargardt disease, conditions that collectively affect millions and share a common challenge: irreversible degeneration of critical retinal cells.
We believe that by targeting upstream signaling pathways that drive synaptic instability, neuroinflammation, and cellular toxicity, we can preserve vision and open new frontiers for treating neurodegeneration systemically.
The Status Quo Isn’t Good Enough
Dry AMD affects 80% of age-related macular degeneration cases—yet has no FDA-approved treatment.
Glaucoma silently steals vision in over 60 million people worldwide by damaging retinal ganglion cells.
Diabetic retinopathy and Stargardt disease cause irreversible damage through inflammation, vascular overgrowth, and toxic cellular buildup.
In these conditions, by the time symptoms appear, irreversible damage has already begun. We’re not just treating symptoms. We’re targeting the root causes, before it’s too late.
Why the Ephrin Receptor Matters
Think of nerve cells as a network of branches. Ephrin signaling is what tells those branches where to grow, when to connect, and when to back off. When it goes haywire, so does everything from axonal growth to blood vessel proliferation.
EIR’s peptidomimetic therapies mimic the body’s natural regulatory signals, essentially restoring the “stop” signs in diseases that cause overgrowth, inflammation, and degeneration.
A Target Therapy Built for Vision (and Beyond)
While our lead indications are retinal diseases, ephrin receptor biology is not eye-specific. The same signaling pathways we target are active in:
CNS repair and neuroinflammation (e.g., Alzheimer’s, Parkinson’s)
Tumor microenvironment and metastasis (e.g., uveal melanoma)
Vascular patterning and endothelial function
By mastering the modulation of ephrin signaling, we aim to develop a broader therapeutic platform with applications across neurodegenerative and proliferative diseases.
Title